Journal Watch

karenskjeiKaren L. Skjei, M.D.
Assistant Professor,
Department of Neurology Co-Director,
Epilepsy Surgery Program Director,
Epilepsy Monitoring Unit,
Norton Children's Hospital

Dr. Karen Skjei is an assistant professor of Neurology and Pediatrics at the University of Louisville. She completed her undergraduate studies at Duke University, and her medical education at the University of California at San Francisco School of Medicine. She completed a residency in Pediatrics and a fellowship in Child and Adolescent Neurology at the Mayo Clinic in Rochester, New York. She completed a fellowship in Neurophysiology and Epilepsy at the Children’s Hospital of Philadelphia. Dr Skjei is currently Editor of the ICNApedia Journal Watch

92 results - showing 61 - 70
1 2 3 4 5 6 7 8 9 10
Ordering
 
0.0
 
0.0 (0)
Dev Med Child Neuro
Dev Med Child Neuro
Updated August 26, 2014 10875 0
Dev Med Child Neurol
Aim The aim of this study was to examine whether vigabatrin treatment had caused visual field defects (VFDs) in children of school age who had received the drug in infancy. Method In total, 35 children (14 males, 21 females; median age 11y, SD 3.4y, range 8–23y) were examined by static Humphrey perimetry, Goldmann kinetic perimetry, or Octopus perimetry. The aetiologies of infantile spasms identified were tuberous sclerosis (n=10), other symptomatic causes (n=3), or cryptogenic (n=22). Results Typical vigabatrin-attributed VFDs were found in 11 out of 32 (34%) children: in one out of 11 children...
 
0.0
 
0.0 (0)
Journal Of Paediatrics And Child Health
Journal Of Paediatrics And Child Health
Updated August 26, 2014 10391 0
J Paediatr Child Health. 2014 Jun 22
Encephalitis is a complex neurological syndrome caused by inflammation of the brain that occurs with highest incidence in children. It is challenging to diagnose and manage due to the variety of aetiologies and non-specific clinical presentations. We discuss the recent progress in clinical case definitions; review recent, large, prospective epidemiological studies; and describe aetiologies. We emphasise infectious causes relevant to children in Australasia but also consider emerging immune-mediated syndromes responsive to immune therapies. We identify priorities for future research in children, given the potential for climate change and international travel to influence the emergence of infectious agents in our...
 
0.0
 
0.0 (0)
Pediatric Neurology
Pediatric Neurology
Updated August 26, 2014 14520 1
Pediatr Neurol. 2014 Jun 6
BACKGROUND: In spite of high occurrence of migraine headaches in school-age children, there are currently no approved and widely accepted pharmacologic agents for migraine prophylaxis in children. Our previous open-label study in children revealed the efficacy of cinnarizine, a calcium channel blocker, in migraine prophylaxis. A placebo-controlled trial was conducted to demonstrate the efficacy and safety of cinnarizine in the prophylaxis of migraine in children.
 
0.0
 
0.0 (0)
Journal Of Nuclear Medicine
Journal Of Nuclear Medicine
Updated August 26, 2014 13732 0
J Nucl Med. 2014 May 5;55(7):1099-110
AIMS: A precise assessment of the drug-resistant epileptic pediatric population for surgical candidacy is often challenging, and to date there are no evidence-based guidelines for presurgical identification of the epileptogenic zone. To evaluate the usefulness of radionuclide imaging techniques for presurgical evaluation of epileptic pediatric patients, we compared the results of video-electroencephalography (EEG), brain MR imaging, interictal SPECT, ictal SPECT, subtraction ictal SPECT coregistered to MR imaging (SISCOM), and interictal PET with 18F-FDG.
 
0.0
 
0.0 (0)
ICNA
ICNA
July 28, 2014 8539 1
Acta Paediatr. 2014 Jul 21
AIMS: There is a need for an objective assessment scoring system to evaluate the effectiveness of prophylactic drugs in paediatric migraine and the aim of this study was to evaluate the Paediatric Migraine Disability Assessment score (PedMIDAS).  
 
0.0
 
0.0 (0)
Dr Paolo Curatolo
Dr Paolo Curatolo
Updated November 21, 2017 10660 0
Tuberous sclerosis complex (TSC) is a genetic multisystem disorder characterized by the development of hamartomas in several organs. Mutations in the TSC1 and TSC2 tumor suppressor genes determin overactivation of the mammalian target of rapamycin (mTOR) signaling pathway and subsequent abnormalities in numerous cell processes. As a result, mTOR inhibitors such as sirolimus and everolimus have the potential to provide targeted therapy for TSC patients. Everolimus has been recently approved as a pharmacotherapy option for TSC patients with subependymal giant-cell astrocytomas (SEGAs) or renal angiomyolipomas (AMLs). However, clinical evidence suggests that this treatment can benefit other TSC-associated disease...
92 results - showing 61 - 70
1 2 3 4 5 6 7 8 9 10

pleasedonate